CERT
Certara, Inc.
Healthcare · Medical - Healthcare Information Services
Deeply Undervalued·Quality 80·RSI 24·DCF +12%·Conviction 73
Investment Thesis — Certara, Inc.
The market is severely mispricing Certara, viewing it as a broken growth story due to recent underperformance and negative EPS, despite its mission-critical software in drug development. This overlooks the sticky nature of its recurring revenue and the high switching costs for its specialized clientele, creating a significant disconnect between its current valuation and long-term potential.
Catalysts
- Return to positive GAAP EPS and free cash flow.
- Significant contract wins or strategic partnerships.
- Successful integration of AI/ML into its software platform, driving new product adoption.
Risk Factors
- Prolonged slowdown in biopharma R&D spending.
- Failure to achieve operational efficiencies and sustained profitability.
- Increased competitive pressure from larger tech players or specialized startups.
Key Debates
Fwd P/E expands to 20x by H1 2025 on 15% growth durability.
Gross Margin expands to 65% by Q1 2025 via software mix shift.
Oversold RSI 20.5 triggers 20% price rebound by Q3 2024.